About Global Stem cell Technology
Global Stem cell Technology is a Healthcare company based in Evergem (Belgium) founded in 2012, and was acquired by Boehringer Ingelheim in July 2020. Blood-derived mesenchymal stem cells are developed for veterinary clinical applications. The company has 14 employees. Its chief executive, as recorded, is Jan Spaas. The company was acqui-hired. Its focus areas include HealthTech, Veterinary HealthTech, Biopharmaceuticals and Companion Animals. Its legal entity is SiteManager.
Company details
GST is a developer of blood-derived mesenchymal stem cells for clinical use in animals. It has developed stem cell products for horses and dogs. It uses various types of steam cell technology such as peripheral blood-derived, immune invasive properties, allogenic-xenogenic, and many more. Products include GST001 that helps the horse suffers from severe cartilage and bone degeneration, surgical procedures, and others. Other products GST002 which is a major component of tendons in collagen Type I, during the tendon healing phases.
- Headquarters Evergem, Belgium
- Employees 14
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website gst.be
- Acquired by Boehringer Ingelheim (Jul 2020)
- Legal Name Sitemanager
- Net Profit-$426.79 K (USD)-190as on Mar 31, 2022
- EBITDA-$258.48 K (USD)-525as on Mar 31, 2022
- Investors
- Employee Count14
- Acquired byBoehringer Ingelheim
(Jul 2020)
Investors in Global Stem cell Technology
Global Stem cell Technology has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boehringer Ingelheim.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Generic drugs and clinical research services are provided globally. | 1885 | boehringer-ingelheim.com |
Investor details for Global Stem cell Technology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Global Stem cell Technology
1 people are tracked at Global Stem cell Technology (1 in leadership); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
Jan Spaas | CEO | Leadership |
Complete people profiles for Global Stem cell Technology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Global Stem cell Technology
2 dated milestones of Global Stem cell Technology across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Global Stem cell Technology is founded.
- Exit Acquired by Boehringer Ingelheim.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Global Stem cell Technology
Global Stem cell Technology was founded in 2012.
Global Stem cell Technology is headquartered in Evergem, Belgium. It is registered at Evergem, Flanders, Belgium.
Jan Spaas is the CEO of Global Stem cell Technology, as recorded in our data.
Global Stem cell Technology has 14 employees.
GST is a developer of blood-derived mesenchymal stem cells for clinical use in animals. It has developed stem cell products for horses and dogs. It uses various types of steam cell technology such as peripheral blood-derived, immune invasive properties, allogenic-xenogenic, and many more. Products include GST001 that helps the horse suffers from severe cartilage and bone degeneration, surgical procedures, and others. Other products GST002 which is a major component of tendons in collagen Type I, during the tendon healing phases.
Global Stem cell Technology has 1 investor. Key investors include Boehringer Ingelheim.
Global Stem cell Technology operates through Sitemanager.
Yes. Global Stem cell Technology was acquired by Boehringer Ingelheim in July 2020.